Study of CDK inhibitor before chemotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug (a CDK inhibitor) given before your regular chemotherapy for triple-negative breast cancer. The goal is to understand how the drug affects the tumor, which might help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have been diagnosed with triple-negative breast cancer that is either stage II, III, or IV.
- Have a tumor in the breast that measures at least 2 cm and can be biopsied.
- Have not received any prior treatment for this breast cancer.
- Be in reasonably good health (able to carry out daily activities) with normal blood counts and organ function.
- Be willing to undergo additional biopsies and an MRI as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This study tests a new drug called trilaciclib, which is added to standard chemotherapy given before breast cancer surgery. The goal is to see if it helps shrink the tumor and possibly reduces side effects like low blood cell counts, making the treatment easier to tolerate.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.